Large scale synthesis and purification of the PGN precursors lipid I and lipid II were performed as previously described (Ling et al., 2015 (link)). UDP-N-acetyl-muramic acid pentapeptide (UDP-MurNAc-pp) was purified according to the protocol elaborated by Kohlrausch and Höltje (Kohlrausch and Höltje, 1991 (link)). Undecaprenyl phosphate (C55P) and undecaprenyl diphosphate (C55PP) were purchased from Larodan Fine Chemicals AB (Malmö, Sweden). The phospholipids 1,2-dioleoyl-sn-glycero-3- phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG) and 1′,3′-bis[1,2-distearoyl-sn-glycero-3-phospho]-glycerol (DOCL, cardiolipin) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). The concentration of purified PGN and wall teichoic acid precursors was quantified on the basis of their phosphate content as described (Rouser et al., 1970 (link)).